Reyvow Alternatives Compared
| Reyvow (lasmiditan) | Ubrelvy (ubrogepant) | Sumatriptan |
|
|---|
| Reyvow (lasmiditan) | Ubrelvy (ubrogepant) | Sumatriptan |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Migraine. Reyvow may also be used for purposes not listed in this medication guide. |
Prescription only
Ubrelvy is a prescription medicine that may be used to treat acute migraine attacks in adults and works by blocking the effects of a protein, called CGRP that is thought to play a role in migraine... View more |
Prescription only
Sumatriptan may be used to quickly relieve the symptoms of a migraine but may not be suitable for everyone including those with pre-existing cardiovascular conditions. Prescribed for Migraine... View more |
Related suggestions Migraine
Popular comparisons
|
|||||||||||||||||||||||
| More about Reyvow (lasmiditan) | More about Ubrelvy (ubrogepant) | More about Sumatriptan | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Reyvow has an average rating of 5.1 out of 10 from a total of 23 ratings on Drugs.com. 48% of reviewers reported a positive effect, while 48% reported a negative effect. |
Ubrelvy has an average rating of 6.4 out of 10 from a total of 266 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 35% reported a negative effect. |
Sumatriptan has an average rating of 7.7 out of 10 from a total of 549 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Reyvow side effects |
View all Ubrelvy side effects |
View all Sumatriptan side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Reyvow prices |
View all Ubrelvy prices |
View all Sumatriptan prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
Imitrex, Imitrex Nasal, Imitrex Statdose, Onzetra Xsail, Tosymra, Zembrace SymTouch | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
5.7 hours |
7 hours |
6 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Some potential for abuse
Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 453 drugs are known to interact with Reyvow:
|
A total of 248 drugs are known to interact with Ubrelvy:
|
A total of 100 drugs are known to interact with Sumatriptan:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
October 11, 2019 |
December 23, 2019 |
January 28, 2016 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.